US2006241025A1PendingUtilityA1

Biodegradable glucosamine-muramyl peptides for apoptosis modulation

Individually held — no corporate assignee on recordPriority: Apr 9, 2003Filed: Jun 21, 2006Published: Oct 26, 2006
Est. expiryApr 9, 2023(expired)· nominal 20-yr term from priority
C12P 21/06C07K 9/005A61K 38/00
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention includes apoptosis modulating glucosamine-muramyl-peptides, obtained by specific endopeptidase digestion of gram positive bacteria, methods of preparation of thereof and medical food compositions for management and treatment of conditions caused by TNF alpha cytotoxicity.

Claims

exact text as granted — not AI-modified
1 . A Biodegradable glucosamine-muramyl-peptides of the general formula  
     
       
         
         
             
             
         
       
     
     where R1 is lysine or ornithine residue, R2 is amino acid residue selected from the group of D-alanine, L-alanine, D-aspartic acid, L-glycine, L-serine, D-serine, and L-threonine, and R3 is amino acid residue selected from the L-glycine, D-asparagine, D-aspartic acid, and D-glutamine.  
   
   
       2 . The composition of  claim 1 , wherein the biodegradable compound is  
     
       
         
         
             
             
         
       
     
   
   
       3 . The composition of  claim 1 , wherein the biodegradable compound is  
     
       
         
         
             
             
         
       
     
   
   
       4 . The composition of  claim 1 , wherein the biodegradable compound is  
     
       
         
         
             
             
         
       
     
   
   
       5 . The composition of  claim 1 , wherein the biodegradable compound is  
     
       
         
         
             
             
         
       
     
   
   
       6 . The composition of  claim 1 , wherein the biodegradable compound is

Join the waitlist — get patent alerts

Track US2006241025A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.